Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...
Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...
In the U.S., revenue climbed 15%, to $1.98 billion, helped by strong demand and higher pricing for its cystic-fibrosis drugs, the company said. Its Casgevy and Journavx drugs, which treat severe ...
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...
Investor's Business Daily on MSN
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
James Chen, CMT is an expert trader, investment adviser, and global market strategist. Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced financial consultant. She has a demonstrated ...
Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Somer G. Anderson is CPA, doctor of accounting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback